急性髓系白血病减低强度预处理采用美法仑方案与白消安方案的比较:CIBMTR报告
该研究比较氟达拉滨/白消安(FB)与氟达拉滨/美法仑(FM)减低强度预处理(RIC)在急性髓系白血病(AML)移植中的结局。共纳入622例FM和791例FB成人患者,FM组移植后3个月内总生存(OS)显著更低(HR=1.82,P<.001),但3个月后OS边缘性更优(HR=0.87,P=.05),无白血病生存(LFS)更优(HR=0.89,P=.05),早期非复发死亡(NRM)显著增加(HR=3.85,P<.001),长期复发更低(HR=0.65,P<.001)。
要点
- FM组移植后3个月内OS显著低于FB组(HR=1.82,P<.001),主要因早期NRM显著增加(HR=3.85,P<.001)。
- FM组3个月后OS边缘性优于FB组(HR=0.87,P=.05),LFS更优(HR=0.89,P=.05)。
- FM组长期复发率显著低于FB组(HR=0.65,P<.001),结论在完全缓解患者中一致。
核心结论
- 与FB相比,FM减低强度预处理显示边缘性更优的长期OS和LFS以及更低的复发率。
- 移植后3个月内OS较低主要归因于早期NRM较高。
研究设计与样本
- 研究为来自国际血液与骨髓移植研究中心(CIBMTR)的成人AML患者队列,接受2001年至2015年间首次RIC异基因移植。
- 排除脐带血或同卵双生移植、预处理含全身照射、以及采用体外T细胞去除进行GVHD预防的患者。
- 共622例接受FM,791例接受FB。
- 主要终点为总生存(OS),次要终点为无白血病生存(LFS)、非复发死亡(NRM)、复发和GVHD;采用多因素生存模型调整患者、白血病和移植相关因素。
主要发现
- 与FB组相比,FM组移植时处于完全缓解(CR)者更少、匹配同胞供者更少、抗胸腺细胞球蛋白或阿仑单抗使用更少。
- FM组更多患者接受骨髓移植物且移植时间早于2005年。
- 移植后3个月内OS在FM组显著更低(HR=1.82,P<.001),但3个月后FM组OS边缘性更优(HR=0.87,P=.05)。
- FM组LFS优于FB组(HR=0.89,P=.05)。
- FM组移植后3个月内NRM显著增加(HR=3.85,P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a lack of large comparative study on the outcomes of reduced intensity conditioning (RIC) in acute myeloid leukemia (AML) transplantation using fludarabine/busulfan (FB) and fludarabine/melphalan (FM) regimens. Adult AML patients from Center for International Blood and Marrow Transplant Research who received first RIC allo-transplant between 2001 and 2015 were studied. Patients were excluded if they received cord blood or identical twin transplant, total body irradiation in conditioning, or graft-versus-host disease (GVHD) prophylaxis with in vitro T-cell depletion. Primary outcome was overall survival (OS), secondary end points were leukemia-free survival (LFS), nonrelapse mortality (NRM), relapse, and GVHD. Multivariate survival model was used with adjustment for patient, leukemia, and transplant-related factors. A total of 622 patients received FM and 791 received FB RIC. Compared with FB, the FM group had fewer transplant in complete remission (CR), fewer matched sibling donors, and less usage of anti-thymocyte globulin or alemtuzumab. More patients in the FM group received marrow grafts and had transplantation before 2005. OS was significantly lower within the first 3 months posttransplant in the FM group (hazard ratio [HR] = 1.82, P < .001), but was marginally superior beyond 3 months (HR = 0.87, P = .05). LFS was better with FM compared with FB (HR = 0.89, P = .05). NRM was significantly increased in the FM group during the first 3 months of posttransplant (HR = 3.85, P < .001). Long-term relapse was lower with FM (HR = 0.65, P < .001). Analysis restricted to patients with CR showed comparable results. In conclusion, compared with FB, the FM RIC showed a marginally superior long-term OS and LFS and a lower relapse rate. A lower OS early posttransplant within 3 months was largely the result of a higher early NRM.
引用
- Zhou Z, Nath R, Cerny J, et al. Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. Blood Adv. 2020. PMID: 32663298. doi:10.1182/bloodadvances.2019001266
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。